MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
22 Junho 2023 - 9:30AM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED),
(the “Company” or “MindMed”), a clinical stage biopharmaceutical
company developing novel product candidates to treat brain health
disorders, announced today that members of the Company’s management
team will participate in the H.C. Wainwright 4th Annual
Neuropsychiatry Virtual Conference:
- H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
- Format: Fireside Chat
- Date and Time: Available as an on-demand session beginning on
Monday, June 26, 2023 at 7:00 am EDT
- Webcast Link: H.C. Wainwright 4th Annual Neuropsychiatry
Virtual Conference
Audio webcasts and replays of available presentations will be
accessible on MindMed’s Investor Resources website for up to 90
days following each event.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the symbol MMED.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230622362857/en/
For Media & Investor Inquiries: Maxim Jacobs, CFA Vice
President, Investor Relations and Corporate Communications Mind
Medicine (MindMed) Inc. ir@mindmed.co media@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024